Teva Completes Acquisition of Anda Inc

Industry Reports
Typography

Teva Pharmaceutical Industries Ltd announced that it has completed its acquisition of Anda, Inc., a leading distributor of generic pharmaceuticals in the U.S., from Allergan plc.

“We are pleased that Anda, Inc., one of the leading distributors of generic medicines in the U.S., is now part of Teva. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for our business and for our extensive supply chain network in particular,” said Siggi Olafsson, President & CEO of Global Generic Medicines. “This acquisition enables us and our customers to provide more patients throughout the country with access to generic medicines."

“We are excited to become part of Teva’s distribution network to support our customers and patients across the country,” said Charles D. Phillips, President & CEO of Anda. “By joining forces with Teva, Anda’s product offerings will significantly increase and we will be able to reach more patients in the United States.”

Teva currently has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one-of-every six generic prescriptions dispensed in the U.S. is filled with a Teva product.

About Teva
Teva Pharmaceutical Industries Ltd is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com


IR Contacts:
Kevin C. Mannix,
United States, 215-591-8912

Ran Meir,
United States, 215-591-3033

Tomer Amitai,
Israel, 972 (3) 926-7656

or

PR Contacts:

Iris Beck Codner,
Israel, 972 (3) 926-7687

Denise Bradley,
United States, 215-591-8974

Nancy Leone,
United States, 215-284-0213